Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor.
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PORTSMAB
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.